Vertex Pharmaceuticals
VRTX
505.64
+3.33
+0.66%
Vertex Pharmaceuticals
US · VRTX
#155 by market cap
Listed 1970
505.64
+3.33
+0.66%
Live - 5344 symbols - heartbeat 436s ago
· 2026-10-08 07:44
Pre-market
505.64
0.00%
After-hours
505.80
+0.03%
Overnight
505.01
-0.12%
- Market cap
- 128.16B
- P/E (TTM)i
- 29.45
- P/Bi
- 6.33
- EPSi
- 15.32
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on VRTX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 24 analysts
Buy
Avg price target
580.21 +14.7%
Price target rangecurrent 505.64
Low350.00
Avg580.21
High665.00
Buy 88%
Hold 8%
Sell 4%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-29 | BofA Securities | -- | BUY | -- |
| 2026-09-28 | UBS | -- | BUY | 615.00 |
| 2026-09-25 | Bernstein | -- | BUY | 608.00 |
| 2026-09-23 | Truist Financial | -- | BUY | -- |
| 2026-09-23 | Scotiabank | -- | BUY | 558.00 |
| 2026-09-23 | Jefferies | -- | BUY | 640.00 |
| 2026-09-23 | BMO Capital | -- | BUY | 600.00 |
| 2026-09-23 | Citi | -- | BUY | 585.00 |
| 2026-09-23 | Barclays | -- | BUY | 617.00 |
| 2026-09-22 | William Blair | -- | BUY | -- |
| 2026-09-22 | UBS | -- | BUY | 585.00 |
| 2026-09-22 | BofA Securities | -- | BUY | 672.00 |
| 2026-09-22 | Morgan Stanley | -- | BUY | 665.00 |
| 2026-09-22 | Stifel | -- | HOLD | -- |
| 2026-09-22 | Goldman Sachs | -- | BUY | 653.00 |
| 2026-09-22 | H.C. Wainwright | -- | BUY | 641.00 |
| 2026-09-16 | Scotiabank | -- | BUY | 558.00 |
| 2026-09-14 | Morgan Stanley | -- | BUY | 665.00 |
| 2026-09-11 | J.P. Morgan | -- | BUY | 560.00 |
| 2026-09-02 | Citi | -- | BUY | 585.00 |
| 2026-09-01 | Morgan Stanley | -- | BUY | 665.00 |
| 2026-08-20 | UBS | -- | BUY | 585.00 |
| 2026-08-17 | BMO Capital | -- | BUY | 600.00 |
| 2026-08-12 | RBC Capital | -- | BUY | 570.00 |
| 2026-08-11 | Bernstein | -- | BUY | 608.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Improving
4
■ Upgrades■ Downgrades
- 4 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: Maxim Group moved from Hold to Buy on 2026-03-18.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-03-18 | Maxim Group | HOLD → BUY | 575.00 |
| 2026-01-22 | RBC Capital | HOLD → BUY | 546.00 |
| 2026-01-12 | Bernstein | HOLD → BUY | -- |
| 2025-12-03 | Morgan Stanley | HOLD → BUY | 516.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-02 | After close | -- | -- |
| 2026/Q2 | 2026-08-03 | After close | ±5.68% | +1.70% (in line) |
| 2026/Q1 | 2026-05-04 | After close | ±5.98% | -1.28% (in line) |
| 2025/Q4 | 2026-02-12 | After close | ±8.09% | +5.69% (in line) |
| 2025/Q3 | 2025-11-03 | After close | ±6.88% | -1.02% (in line) |
| 2025/Q2 | 2025-08-04 | After close | ±6.72% | -20.60% (beat) |
| 2025/Q1 | 2025-05-05 | After close | ±4.62% | -10.03% (beat) |
| 2024/Q4 | 2025-02-10 | After close | ±4.80% | -3.14% (in line) |
| 2024/Q3 | 2024-11-04 | After close | ±5.30% | +5.73% (beat) |
| 2024/Q2 | 2024-08-01 | After close | ±5.13% | -2.24% (in line) |
| 2023/Q4 | 2024-02-05 | After close | ±4.66% | -2.98% (in line) |
| 2023/Q3 | 2023-11-06 | After close | ±3.97% | -1.95% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:44:06 · For reference only, not investment advice and not tailored to your situation.